Key result
Aspirin exposure in patients with cerebrovascular disease markedly suppressed thromboxane B2 synthesis from arachidonic acid, requiring at least 750 mg/day for nearly complete suppression.
Why the study?
Does oral aspirin suppress thromboxane B2 generation from arachidonic acid or prostaglandin H2 in patients with cerebrovascular disease?
Observational (n=97)
Does oral aspirin suppress thromboxane B2 generation from arachidonic acid or prostaglandin H2 in patients with cerebrovascular disease?
Oral aspirin suppresses thromboxane B2 synthesis from arachidonic acid but not from prostaglandin H2 in patients with cerebrovascular disease, requiring at least 750 mg/day for complete suppression.
The ability of platelets to synthesize thromboxane B2 (TxB2) from arachidonic acid (AA) or prostaglandin H2 (PGH2) was studied in 26 control subjects, 40 patients with essential hypertension, 20 patients with cerebrovascular disease (CVD) not taking aspirin and 11 patients with CVD taking aspirin. The activity of platelets to form TxB2 from AA or PGH2 was measured using 1-14C arachidonic acid or 1-14C PGH2 as a substrate. There was no significant difference in TxB2 generation from AA or PGH2 among the platelets collected from the control subjects, hypertensive patients and CVD patients not taking aspirin. In CVD patients taking aspirin, marked suppression was observed in TxB2 synthesis from AA, but no suppression in TxB2 synthesis from PGH2. At least 750 mg aspirin per day were required for nearly complete suppression of TxB2 generation from AA.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (1980) conducted an observational in Essential hypertension or cerebrovascular disease (n=97). Aspirin vs. No aspirin (controls, hypertensive patients, and CVD patients not taking aspirin) was evaluated on Thromboxane B2 (TxB2) generation from arachidonic acid (AA) or prostaglandin H2 (PGH2). Aspirin exposure in patients with cerebrovascular disease markedly suppressed thromboxane B2 synthesis from arachidonic acid, requiring at least 750 mg/day for nearly complete suppression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: